Adding Cetuximab to Definitive Chemoradiation for Esophageal Cancer

To the Editor We read with interest the article by Suntharalingam et al demonstrating that the addition of cetuximab to concurrent chemoradiation therapy did not improve overall survival in the nonoperative treatment of patients with esophageal cancer. Although the study stratified patients according to tumor histologic type, it was not powered to assess with certainty the benefit of cetuximab therapy in each of the 2 main histological variants of this disease.

https://ift.tt/2GGKdU6